OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
461030$6620.0057

IMBDX Inc

Biotechnology & Medical ResearchVerified

IMBDX Inc has a strong liquidity position, with a current ratio of 15.37 and cash and equivalents of KRW 2,081,621,720, indicating a robust ability to meet short-term obligations. The company's price-to-book ratio of 3.69 suggests that the market values the company at a premium to its book value, while the price-to-tangible-book ratio is identical, indicating no intangible asset discount. The company's debt-to-equity ratio of 0.02 reflects a conservative capital structure with minimal leverage. Profitability metrics show a challenging performance, with a return on equity of -0.3153 and a return on assets of -0.2925, indicating significant losses relative to equity and total assets. The company reported a net loss of KRW 7,933,872,390 and an operating loss of KRW 8,664,254,150, which are well below the industry median for profitability metrics. Gross profit of KRW 1,386,243,830 is also below the industry median, suggesting operational inefficiencies or pricing pressures. The company's revenue is derived from laboratory analysis services and diagnostic product sales, with no disclosed segment breakdown. The geographic exposure is not specified, but the company operates in both domestic and overseas markets. Revenue concentration data is not available, but the lack of segment details suggests a need for further transparency. The company's growth trajectory is uncertain, with no specific outlook provided for the current or next fiscal year. The operating cash flow of -KRW 6,202,213,770 and free cash flow of -KRW 7,508,337,410 indicate a cash outflow, which could constrain growth initiatives. The capital expenditure of -KRW 1,002,240,350 suggests ongoing investment, but the negative value indicates a cash outflow. Risk factors include a low liquidity risk and low dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's dilution potential is low, and no adjustments were applied to the valuation metrics. The risk assessment indicates a low overall risk profile, but the financial losses and negative cash flows suggest operational and financial risks that need monitoring. Recent events include the latest financial filing, which shows a significant net loss and negative cash flows. No recent transcripts or filings beyond the financial snapshot are available for analysis.

30-day price · 461030-1260.00 (-19.5%)
Low$5060.00High$7720.00Close$5200.00As of21 May, 00:00 UTC
Profile
CompanyIMBDX Inc
Ticker461030.KQ
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. IMBDX Inc is a Korea-based company engaged in the provision of laboratory analysis services, including clinical diagnosis and genetic analysis based on liquid biopsy technology, as well as the development, manufacture, and sale of diagnostic products in domestic and overseas markets.

Classification. IMBDX Inc is classified under the Healthcare economic sector, Pharmaceuticals & Medical Research business sector, and Biotechnology & Medical Research industry, with a classification confidence of 0.92.

IMBDX Inc has a strong liquidity position, with a current ratio of 15.37 and cash and equivalents of KRW 2,081,621,720, indicating a robust ability to meet short-term obligations. The company's price-to-book ratio of 3.69 suggests that the market values the company at a premium to its book value, while the price-to-tangible-book ratio is identical, indicating no intangible asset discount. The company's debt-to-equity ratio of 0.02 reflects a conservative capital structure with minimal leverage. Profitability metrics show a challenging performance, with a return on equity of -0.3153 and a return on assets of -0.2925, indicating significant losses relative to equity and total assets. The company reported a net loss of KRW 7,933,872,390 and an operating loss of KRW 8,664,254,150, which are well below the industry median for profitability metrics. Gross profit of KRW 1,386,243,830 is also below the industry median, suggesting operational inefficiencies or pricing pressures. The company's revenue is derived from laboratory analysis services and diagnostic product sales, with no disclosed segment breakdown. The geographic exposure is not specified, but the company operates in both domestic and overseas markets. Revenue concentration data is not available, but the lack of segment details suggests a need for further transparency. The company's growth trajectory is uncertain, with no specific outlook provided for the current or next fiscal year. The operating cash flow of -KRW 6,202,213,770 and free cash flow of -KRW 7,508,337,410 indicate a cash outflow, which could constrain growth initiatives. The capital expenditure of -KRW 1,002,240,350 suggests ongoing investment, but the negative value indicates a cash outflow. Risk factors include a low liquidity risk and low dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's dilution potential is low, and no adjustments were applied to the valuation metrics. The risk assessment indicates a low overall risk profile, but the financial losses and negative cash flows suggest operational and financial risks that need monitoring. Recent events include the latest financial filing, which shows a significant net loss and negative cash flows. No recent transcripts or filings beyond the financial snapshot are available for analysis.
Key takeaways
  • IMBDX Inc has a strong liquidity position with a current ratio of 15.37 and significant cash reserves.
  • The company is experiencing significant financial losses, with a return on equity of -0.3153 and a return on assets of -0.2925.
  • The company's capital structure is conservative, with a debt-to-equity ratio of 0.02 and minimal leverage.
  • The company's growth trajectory is uncertain, with negative operating and free cash flows.
  • The risk assessment indicates a low liquidity and dilution risk, but the financial performance suggests operational and financial risks.
  • The company operates in both domestic and overseas markets, but revenue concentration and segment details are not disclosed.
  • --
  • # RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyKRW
Revenue$5.33B
Gross profit$1.39B
Operating income-$8.66B
Net income-$7.93B
R&D
SG&A
D&A
SBC
Operating cash flow-$6.20B
CapEx-$1.00B
Free cash flow-$7.51B
Total assets$27.12B
Total liabilities$1.96B
Total equity$25.16B
Cash & equivalents$2.08B
Long-term debt$437.7M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$6620.00
Market cap$92.80B
Enterprise value$91.15B
P/E
Reported non-GAAP P/E
EV/Revenue17.1
EV/Op income
EV/OCF
P/B3.7
P/Tangible book3.7
Tangible book$25.16B
Net cash$1.64B
Current ratio15.4
Debt/Equity0.0
ROA-29.2%
ROE-31.5%
Cash conversion78.0%
CapEx/Revenue-18.8%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 1 companies
Metric461030Activity
Op margin-162.6%-2.9% medp25 -218.9% · p75 9.6%below median
Net margin-148.9%28.2% medp25 28.2% · p75 28.2%bottom quartile
Gross margin26.0%47.8% medp25 27.6% · p75 68.9%bottom quartile
CapEx / revenue-18.8%6.6% medp25 6.6% · p75 6.6%bottom quartile
Debt / equity2.0%271.5% medp25 271.5% · p75 271.5%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 06:56 UTC#f472c7c8
Market quoteclose KRW 6620.00 · shares 0.01B diluted
no public URL
2026-05-10 06:56 UTC#42ec294a
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 06:58 UTCJob: d2a3382e